Evaluating metastatic colorectal cancer patients in Finland
A Population-based Prospective Study to Evaluate Clinical Behaviour, Resectability and Survival in 1st Line Metastatic Colorectal Cancer (CRC) Patients in Finland
This study looks at how well different treatments work for people in Finland with advanced colorectal cancer and how these treatments affect their survival and tumor behavior.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Helsinki University Central Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Helsinki) |
| Trial ID | NCT01531621 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical behavior, resectability, and survival outcomes of patients with first-line metastatic colorectal cancer (CRC) in Finland. It will evaluate the efficacy of chemotherapy and targeted therapies, measuring overall response rates, progression-free survival, and overall survival. Additionally, the study will analyze biomarkers and DNA polymorphisms to predict treatment effects and tumor behavior. The research will involve biomarker sampling and data collection from hospital charts without direct patient contact.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with histologically confirmed metastatic colorectal cancer who are starting or undergoing first-line chemotherapy.
Not a fit: Patients with non-metastatic colorectal cancer or those not receiving first-line chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the treatment and management of metastatic colorectal cancer, potentially improving patient outcomes.
How similar studies have performed: Other studies focusing on metastatic colorectal cancer have shown promising results, indicating that this approach is supported by previous research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with histologically confirmed CRC, who are scheduled to start or are getting first line chemotherapy for metastatic disease 2. Age \> 18 3. Metastatic disease (including locally advanced disease not amenable with surgery and/or (chemo)radiotherapy) 4. Signed written informed consent according to ICH/GCP and the local regulations (approved by the Independent Ethics Committee \[IEC\]) will be obtained prior to study 5. No informed consent will be obtained from patients participating in the data collection study obtaining data from hospital charts. No blood sampling, nor contacting of patients will be performed.
Where this trial is running
Helsinki
- Department of Oncology — Helsinki, Finland (Recruiting)
Study contacts
- Principal investigator: Pia Osterlund, MD — Helsinki University Central Hospital
- Study coordinator: Pia Osterlund, MD
- Email: pia.osterlund@hus.fi
- Phone: +358-9-4711
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.